<DOC>
	<DOCNO>NCT01911442</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study design evaluate efficacy safety 2 fixed dos lurasidone ( 20 mg/day 60 mg/day ) 6 week compare placebo pediatric adolescent subject irritability associate autistic disorder reside community setting .</brief_summary>
	<brief_title>Lurasidone Pediatric Autism Study</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled study design evaluate efficacy safety 2 fixed dos lurasidone ( 20 mg/day 60 mg/day ) 6 week compare placebo pediatric adolescent subject irritability associate autistic disorder reside community setting .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Written inform consent parent ( ) legal guardian ( ) sufficient intellectual capacity understand study support subject ' adherence study procedure must obtain subject emancipate . In accordance Institutional Review Board ( IRB ) requirement , subject complete inform assent developmentally appropriate , participate study conduct studyspecific procedure . Male female subject 6 17 year age , inclusive , time consent . A reliable informant ( eg , parent , legal guardian , caregiver ) past current direct knowledge subject must accompany subject visit must oversee administration study drug . DSMIVTR primary diagnosis autistic disorder confirmation diagnosis train clinician ( eg , psychiatrist , psychologist , social worker , etc ) time screen , mean Autism Diagnostic Interview , Revised ( ADIR ) . Screening Baseline ABC irritability subscale score ≥ 18 . Screening Baseline CGIS ≥ 4 . Within 5th 95th percentile gender specific Growth Charts Centers Disease Control ( CDC ) . No clinically relevant abnormal laboratory value . No clinically relevant abnormal vital sign values/findings 1 . Females participate study : unable become pregnant ( eg , premenarchal , surgically sterile , etc . ) OR practice true abstinence ( consistent lifestyle ) must agree remain abstinent signing informed consent least 7 day last dose study drug take ; OR •are sexually active willing use medically effective method birth control ( eg , male use condom female use condom , diaphragm , contraceptive sponge , spermicide , contraceptive pill , intrauterine device ) signing informed consent least 7 day last dose study drug take . Males must willing remain sexually abstinent ( consistent lifestyle ) use effective method birth control ( eg , male use condom female use condom , diaphragm , contraceptive sponge , spermicide , contraceptive pill , intrauterine device ) signing informed consent least 7 day last dose study drug take . In judgment investigator , subject able swallow size number study drug tablet specify per protocol ( See Table 4 study drug tablet size ) . Able adhere protocolspecified meal requirement dose . Have stable living arrangement least 3 month prior screen . Nonpharmacologic therapy ( eg , behavior modification ) must stable least 4 week screen consistent throughout study . Subjects profound intellectual disability . Current diagnosis bipolar disorder , psychosis , schizophrenia major depression , childhood disintegrative disorder confirm MINIKid ( appropriate ) screening . Confirmed genetic disorder cognitive behavioral disturbance also exclusionary . Clinically significant neurological , metabolic ( include type 1 type 2 diabetes ) , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , carcinoma , and/or urological disorder would pose risk subject participate study might confound result study . Note : Active medical condition minor wellcontrolled exclusionary affect risk subject study result . In case impact condition upon risk subject study result unclear , Medical Monitor consult . Any subject know cardiovascular disease condition ( even control ) must discuss Medical Monitor screening . Evidence chronic organic disease CNS tumor , inflammation , active seizure disorder , vascular disorder , potential CNS relate disorder might occur childhood eg , Duchenne Muscular dystrophy , myasthenia gravis , neurologic serious neuromuscular disorder . In addition , subject must history persistent neurological symptom attributable serious head injury . Past history febrile seizure , druginduced seizure , alcohol withdrawal seizure exclusionary . If subject history seizure , subject must currently take antiepileptic drug ( AEDs ) seizurefree least 6 month . Clinically significant finding ( ) physical examination determine investigator pose health concern subject study . A history presence abnormal ECG , investigator 's opinion clinically significant . Screening ECGs centrally overread , eligibility determine base overread . Known history presence clinically significant intolerance antipsychotic medication include limited angioedema , serotonin neuroleptic malignant syndrome , severe dystonia , moderate severe tardive dyskinesia . Clinically significant alcohol abuse/dependence drug abuse/dependence base Mini International Neuropsychiatric Interview child adolescent ( MINIKid ) criterion within last 6 month prior screen . Clinically significant orthostatic hypotension ( ie , drop systolic blood pressure 20 mmHg and/or drop diastolic blood pressure 10 mmHg within 4 minute stand ) . Presence history ( within last year ) medical surgical condition ( eg , gastrointestinal disease ) might interfere absorption , metabolism , excretion orally administer lurasidone . Positive test result screen : 1 . Urine drug abuse ( amphetamine , barbiturate , benzodiazepine , cocaine , opiates , phencyclidine , cannabinoids , methamphetamine , methadone ) . However , positive test amphetamine , barbiturate , opiate , benzodiazepine methadone may result exclusion subject investigator determines positive test result prescription medicine ( ) . 2 . Pregnancy test ( female subject ≥ 11 year old ) . Lifetime history human immunodeficiency virus ( HIV ) positive acquire immune deficiency syndrome ( AIDS ) , history Hepatitis B C. Participated another interventional clinical trial receive investigational product within 30 day prior study drug administration . Use concomitant medication consistently prolong QT/QTc interval within 28 day prior randomization . Received depot neuroleptic unless last injection least 1 month 1 treatment cycle prior screening , whichever longer . Subject receive treatment antidepressant within 3 day , fluoxetine hydrochloride time within 21 day , MAO inhibitor within 21 day randomization clozapine within 120 day randomization . Depot neuroleptic must discontinue least one treatment cycle prior randomization . Use antipsychotic medication ( study drug ) , carbamazepine , oxcarbazepine fluvoxamine , within 3 day prior randomization . Females pregnant , lactating , likely become pregnant study . Donation whole blood within 60 day prior randomization . Has prolactin concentration great equal 100 ng/mL screening . Subject consider investigator imminent risk suicide study . Subject history one serious suicide attempt ( base investigator 's judgment ) 12 month prior screen . Subjects determine risk suicide injury , assess investigator screening , refer psychiatric evaluation . Clinically relevant history drug hypersensitivity lurasidone component formulation . Subject require use concomitant medication potent inducer inhibitor cytochrome P450 ( CYP ) 3A4 enzyme system ( Appendix C ) signing informed consent followup .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Autism , Lurasidone , Latuda</keyword>
</DOC>